John Castle

Inventing & translating technologies for therapies. ML AI ‘omics & comp biology. Molecular glue for targeted protein degraders. @MonteRosaTx Tweets my own

[MidCurveCapital @midwit_capital]

Great interview with $GLUE CEO @markus_warmuth:
"I'm looking forward for the world to learn more about how Novartis thinks about the program and how broadly their hoping to develop MRT-6160." https://t.co/zNeUEHDS0n

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

We’re turning scientific insight into meaningful progress for heart health – advancing a new way to treat inflammation in ASCVD by targeting the NLRP3/NEK7 pathway upstream. Our NEK7-directed molecular glue degrader, MRT-8102, is designed to stop NLRP3 activation at the source.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today, we announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). https://t.co/K2Km9AsHMf

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

It’s not “just” cholesterol. The role of inflammation in atherosclerotic cardiovascular disease (ASCVD) is gaining increased attention.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study.

Read the full data release here:
https://t.co/pTtJed9hnD

[Zavain Dar @zavaindar]

congrats @MonteRosaTx ($GLUE) on this morning's stunning data from MRT-8102, showing potent NEK7 degradation and potential best in class removal of hsCRP in a daily oral format. this is a potential game changer for ASCVD

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. https://t.co/pTtJed9hnD

[John Castle @joccastle]

Great news today from Monte Rosa. Kudos to the team and a shout out to our scientists who discovered this promising program. Degrading proteins, making medicines.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.

[John Castle @joccastle]

Pleasure working with a tremendous team to transform degraders into medicines.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Our invited review in @TrendsinBiotech is now out in print. The piece explores how machine learning can predict de novo protein–protein interactions, including those induced by our molecular glues.

Kudos to the team for their leadership in this field: https://t.co/akVSnDFyan

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism.

Read the full paper in @NatureComms: https://t.co/zT9ZHO98gi

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today we announced our second collaboration with @Novartis to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: https://t.co/Jcu2LAu5zH

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. https://t.co/jkc5Yt8Hi5

[BiotechTV @BiotechTV]

𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐞𝐧𝐞𝐬: BiotechTV visited @MonteRosaTx in Boston, MA yesterday and learned about the work they are doing on molecular glue degraders. Scientist Katherine Jones showed us some of the equipment that makes it happen.

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @MonteRosaTx's CEO @markus_warmuth updates us on the company's progress in developing molecular glue degraders. $GLUE

Full video: https://t.co/qONd5Ebw0R

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐢𝐧𝐠 𝐒𝐨𝐨𝐧: BiotechTV visited @MonteRosaTx in Boston today and spoke with @markus_warmuth about the latest in molecular glue degraders. Watch for the full episode later this afternoon.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

We’re excited to announce the first subjects have been dosed in a Phase 1 study of MRT-8102, a NEK7-directed MGD being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1β, and IL-6.

Learn more: https://t.co/vyP0ahgFkw

[Markus Warmuth @markus_warmuth]

40yrs LiveAid! 40 years ago at 6.41pm Queen came on stage for their legendary performance! When we had to name our @MonteRosaTx product engine we wanted it to represent greatness and doing the impossible. So we picked QuEEN! Best choice ever! Aye-Oh!

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of @ScienceMagazine.

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

We’ve shown the molecular glue target space is broader than previously understood and we believe we're uniquely positioned to harness its potential: https://t.co/6oUma2tve1